99 related articles for article (PubMed ID: 23485467)
1. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Kato Y; Natsume A; Kaneko MK
Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
[TBL] [Abstract][Full Text] [Related]
2. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
5. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
6. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
7. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
[TBL] [Abstract][Full Text] [Related]
9. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
[TBL] [Abstract][Full Text] [Related]
10. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
[TBL] [Abstract][Full Text] [Related]
11. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
14. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody specific for IDH1 R132H mutation.
Capper D; Zentgraf H; Balss J; Hartmann C; von Deimling A
Acta Neuropathol; 2009 Nov; 118(5):599-601. PubMed ID: 19798509
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
17. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
Pang B; Durso MB; Hamilton RL; Nikiforova MN
Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
[TBL] [Abstract][Full Text] [Related]
18. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
[TBL] [Abstract][Full Text] [Related]
19. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Kato Y; Kaneko MK
Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262
[TBL] [Abstract][Full Text] [Related]
20. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]